CRON vs DFTX: stock comparison and AI forecast
Cronos Group Inc. (CRON) and Definium Therapeutics, Inc. (DFTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CRON Cronos Group Inc.
- Market Cap
- $1.25B
- P/E Ratio
- 19.9x
- Size
- small-cap
- AI Forecast
DFTX Definium Therapeutics, Inc.
- Market Cap
- $4.88B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DFTX is 3.9 times larger than CRON by market capitalization ($4.88B against $1.25B).
- DFTX carries 0.21 times debt per unit of equity, against 0.06 times for CRON.
- Both companies share the SEC industry classification Medicinal Chemicals & Botanical Products.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CRON | DFTX |
|---|---|---|
| Market Cap | $1.25B | $4.88B |
| P/E Ratio | 19.88x | – |
| P/B Ratio | 1.17x | 5.31x |
| EPS | $0.17 | $-3.00 |
| Book Value/Share | $2.90 | $6.84 |
| Revenue/Share | $0.64 | – |
| FCF/Share | $0.14 | – |
Profitability & Margins
| Metric | CRON | DFTX |
|---|---|---|
| ROE | 6.5% | -38.5% |
| ROA | 5.9% | -31.8% |
| ROIC | -0.2% | -23.8% |
| Gross Margin | 34.7% | – |
| Operating Margin | -1.0% | – |
| Net Margin | 29.6% | – |
| EBT Margin | 28.9% | – |
| Tax Rate | -15.7% | – |
Financial Health
| Metric | CRON | DFTX |
|---|---|---|
| Current Ratio | 16.18x | 6.95x |
| Quick Ratio | 15.25x | – |
| D/E Ratio | 0.06x | 0.21x |
| Financial Leverage | 1.10x | 1.21x |
| Interest Coverage | 34.4x | -60.9x |
| Working Capital | $856M | $935M |
Cash Flow
| Metric | CRON | DFTX |
|---|---|---|
| Operating Cash Flow | $60M | -$168M |
| Free Cash Flow | $50M | – |
| Capital Spending | -$10M | – |
| OCF Growth YoY | 199.9% | – |
| FCF/Sales | 21.0% | – |
| CapEx/Sales | 4.3% | – |
Operational Efficiency
| Metric | CRON | DFTX |
|---|---|---|
| Asset Turnover | 0.20x | – |
| Receivables Turnover | 6.5x | – |
| Fixed Assets Turnover | 1.7x | – |
| Days Sales Outstanding | 57 days | – |
Income Statement
| Metric | CRON | DFTX |
|---|---|---|
| Total Revenue | $237M | – |
| Operating Income | -$2M | -$228M |
| Net Income | $70M | -$354M |
| R&D Expense | $5M | $155M |
| SG&A Expense | $81M | – |
Dividend & Shareholder Information
| Metric | CRON | DFTX |
|---|---|---|
| Shares Outstanding | 368M | 134M |
| Net Income Growth | 278.5% | – |
| EPS Growth | 466.7% | – |
CRON vs DFTX: stock comparison and AI forecast
Which is bigger, CRON or DFTX?
DFTX is 3.9 times larger than CRON by market capitalization ($4.88B against $1.25B).
Which one does Intratio's AI model rank higher, CRON or DFTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.